BR100 Increased By (0.95%)
BR30 Increased By (1.11%)
KSE100 Increased By (0.75%)
KSE30 Increased By (0.82%)
BECO 5.35 Increased By ▲ 0.03 (0.56%)
BML 56.98 Increased By ▲ 1.89 (3.43%)
BOP 35.31 Increased By ▲ 0.27 (0.77%)
CNERGY 8.20 Increased By ▲ 0.11 (1.36%)
DCL 11.55 Increased By ▲ 0.19 (1.67%)
FCCL 57.94 Increased By ▲ 1.75 (3.11%)
FCSC 4.91 Decreased By ▼ -0.10 (-2%)
FFL 17.91 Increased By ▲ 0.23 (1.3%)
FNEL 1.25 Increased By ▲ 0.01 (0.81%)
HUMNL 11.17 Increased By ▲ 0.24 (2.2%)
KEL 8.65 Increased By ▲ 0.08 (0.93%)
KOSM 6.57 Increased By ▲ 0.08 (1.23%)
MLCF 107.30 Increased By ▲ 0.79 (0.74%)
NBP 201.40 Increased By ▲ 1.64 (0.82%)
PACE 11.08 Increased By ▲ 0.06 (0.54%)
PAEL 45.65 Increased By ▲ 0.65 (1.44%)
PIAHCLA 30.25 Increased By ▲ 1.68 (5.88%)
PIBTL 18.43 Increased By ▲ 0.16 (0.88%)
PPL 247.08 Increased By ▲ 2.59 (1.06%)
PRL 35.19 Increased By ▲ 0.25 (0.72%)
PTC 66.15 Increased By ▲ 0.33 (0.5%)
SEARL 94.90 Increased By ▲ 0.85 (0.9%)
SSGC 31.08 Increased By ▲ 0.25 (0.81%)
TELE 8.76 Increased By ▲ 0.06 (0.69%)
THCCL 65.72 Increased By ▲ 0.73 (1.12%)
TPLP 10.60 Increased By ▲ 0.34 (3.31%)
TREET 25.05 Increased By ▲ 0.18 (0.72%)
TRG 63.90 Increased By ▲ 0.54 (0.85%)
WAVES 10.79 Increased By ▲ 0.14 (1.31%)
WTL 1.26 Increased By ▲ 0.02 (1.61%)
World

Rovi to make active agents for Moderna COVID-19 vaccine

  • Rovi will start manufacturing of the active agents at its plant in Granada, having previously only packaged vaccines that had been produced in Switzerland, it said in a statement.
Published April 12, 2021 Updated April 12, 2021 02:16pm
By

MADRID: Spanish pharmaceuticals company Rovi plans to start making the active agents for up to 100 million doses of the COVID-19 vaccine developed by Moderna , it said on Monday without disclosing the size of the investment.

Rovi will start manufacturing of the active agents at its plant in Granada, having previously only packaged vaccines that had been produced in Switzerland, it said in a statement.

Madrid-based Rovi, which already has an agreement with Moderna to fill vials and package its vaccines, expects to start supplying markets other than the United States in the third quarter of 2021, the statement said.

Comments

Comments are closed for this article.